MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock and...
$239,972K
Proceeds from issuance of
common stock in...
$60,801K
(24615.85%↑ Y/Y)
Employee stock purchase
plan purchases
$291K
(48.47%↑ Y/Y)
Proceeds from exercises
of common stock...
$78K
(1200.00%↑ Y/Y)
Net cash provided by
financing activities
$287,498K
(52.82%↑ Y/Y)
Canceled cashflow
$13,644K
Net increase in
cash, cash...
$98,850K
(68.48%↑ Y/Y)
Canceled cashflow
$188,648K
Payments of common stock
and pre-funded...
$13,644K
Equity-based compensation
expense
$10,768K
(66.02%↑ Y/Y)
Change in fair value of
derivative liabilities
-$2,500K
(1.96%↑ Y/Y)
Non-cash lease expense
$1,257K
(8.18%↑ Y/Y)
Accounts payable
$1,139K
(143.90%↑ Y/Y)
Depreciation and
amortization expense
$786K
(-0.88%↓ Y/Y)
Other
-$25K
(54.55%↑ Y/Y)
Proceeds from maturities
of...
-$146,880K
(-112.87%↓ Y/Y)
Net cash used in
operating activities
-$99,817K
(-44.12%↓ Y/Y)
Net cash used in
investing activities
-$88,831K
(-47.57%↓ Y/Y)
Canceled cashflow
$16,475K
Canceled cashflow
$146,880K
Net loss
-$111,536K
(-41.61%↓ Y/Y)
Purchases of
available-for-sale securities
$235,396K
(82.79%↑ Y/Y)
Amortization of discount on
available-for-sale securities
$1,984K
(148.00%↑ Y/Y)
Accrued expenses and
other liabilities
-$1,442K
(-185.07%↓ Y/Y)
Change in operating
lease liability
-$1,006K
(-18.63%↓ Y/Y)
Prepaid expenses and
other assets
$324K
(-84.27%↓ Y/Y)
Purchases of property and
equipment
$315K
(-37.38%↓ Y/Y)
Back
Back
Cash Flow
Solid Biosciences Inc. (SLDB)
Solid Biosciences Inc. (SLDB)
source: myfinsight.com